Paradigm Biopharmaceuticals ( (AU:PAR) ) has shared an announcement.
Paradigm Biopharmaceuticals has announced a General Meeting to seek shareholder approval for two key resolutions. The first resolution involves ratifying the issuance of 40 million shares to raise $16 million, which will support the company’s Phase 3 clinical trial for iPPS in osteoarthritis and other operational needs. The second resolution proposes amendments to the company’s constitution, including provisions for virtual shareholder meetings and updates to comply with ASX Listing Rule changes. These measures aim to enhance Paradigm’s financial flexibility and operational efficiency, potentially impacting its market positioning and stakeholder engagement.
More about Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals Ltd. is a late-stage drug development company focused on improving patients’ health by developing pharmaceutical therapies. The company is currently working on iPPS for treating diseases where inflammation is a key factor, such as osteoarthritis and mucopolysaccharidosis.
YTD Price Performance: -50.74%
Average Trading Volume: 10,782
Technical Sentiment Signal: Strong Buy
Current Market Cap: $74.57M
For detailed information about PAR stock, go to TipRanks’ Stock Analysis page.